The largest proposed acquisition in drug-industry history may spark further deals as AstraZeneca Plc tries to sort out alternatives to Pfizer Inc.’s unsolicited 58.8-billion-pound ($98.7 billion) takeover approach.
Pfizer Inc.’s experimental breast cancer drug stopped progression of an incurable form of the disease for more than two years in a study, a dramatic delay for those with the second-deadliest cancer in women.
Bayer AG’s possible sale of its $10 billion plastics unit would accelerate a retreat from chemicals that the maker of Aspirin initiated a decade ago, leaving it focused on the more lucrative life-science industry.
Merck KGaA Chief Financial Officer- designate Matthias Zachert may make his first task repairing the German company’s relationship with investors and analysts as he seeks to revive one of Europe’s worst-performing drug stocks.
When Roche Holding AG executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals or health-care legislation.
Patients taking Novartis AG’s experimental once-daily treatment for smoker’s cough showed a significant improvement in lung function over those on an existing medicine marketed by GlaxoSmithKline Plc, which is also developing a successor drug.